Fortis Healthcare Limited shareholders approved a final dividend of ₹1 per equity share for the financial year ended March 31, 2026 (FY26), during the company’s 30th Annual General Meeting held on August 11, 2026. The meeting, conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM) in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India circulars, also saw the re-appointment of two retiring directors and the ratification of cost auditor remuneration.

The proceedings were chaired by Chairman Leo Puri, who was joined by Vice Chairman Dr. Prem Kumar Nair, Managing Director & CEO Dr. Ashutosh Raghuvanshi, and other key managerial personnel. The Company Secretary confirmed the presence of the requisite quorum before the meeting commenced. Statutory Registers required under the Companies Act, 2013 were made available for inspection during the session. The reports of the Statutory Auditors and Secretarial Auditors contained no qualifications, observations, or adverse remarks.

Ordinary Business Resolutions

Shareholders considered and passed several ordinary resolutions pertaining to routine statutory matters. The key outcomes included:

The audited financial statements for FY26, along with the Board of Directors’ and Auditors’ reports, were taken as read and adopted by the members.

Special Business Resolutions

The AGM also addressed special business items requiring shareholder approval. Shareholders approved the ratification of remuneration to M/s. Jitender, Navneet & Co., (Firm Registration No.: 000119), serving as Cost Auditors for the financial year ended March 31, 2026. Additionally, a special resolution was passed to approve the payment of commission to Independent Directors for a three-year period effective from April 1, 2027, to March 31, 2030.

Another special resolution addressed the payment of remuneration by way of Independent Director Fees to Mr. Leo Puri for the financial year 2025-26. This approval was necessary as his fees exceeded fifty percent of the total annual remuneration payable to all Non-Executive Directors of the company.

Governance and Voting Process

Remote e-voting commenced on August 06, 2026, at 9:00 AM and concluded on August 10, 2026, at 5:00 PM. Members present at the AGM who had not voted remotely were provided an e-voting facility on the NSDL platform using their login credentials. Mr. Mukesh Agarwal, Company Secretary in Whole Time Practice, was appointed as the scrutinizer to ensure fair and transparent voting.

The Chairman declared the e-voting window open for 30 minutes during the live session. The proceedings were deemed concluded at 12:45 Hours (IST). The final results of the voting are scheduled to be announced on or before 6:00 PM (IST) on Thursday, August 13, 2026, and will be posted on the company’s website, the stock exchanges (BSE and NSE), and the NSDL website.

Fortis Healthcare has provided detailed operational and financial guidance through its latest concall update, outlining key margin levers, capital expenditure plans, and growth targets across its hospital and diagnostic segments for FY27 and beyond.

Margin Improvement Levers and FY28 Target

Management maintained its consolidated EBITDA margin guidance for FY27, with a clear target of achieving a 25% EBITDA margin by FY28, inclusive of ESOP costs. The company expects operational improvements to offset the impact of ESOP-related expenses. Key levers identified for margin improvement include:

• Transition of new units — Manesar, Noida, and FMRI — to positive EBITDA contribution
• Improved collections from government bodies and third-party administrators (TPAs)
• Increased occupancy levels at existing hospitals, specifically BG Road and Mulund

Capital Expenditure and Inorganic Growth

Fortis Healthcare has approved a significant capital investment to strengthen its clinical capabilities. The company has also signalled its intent to pursue external growth opportunities.

In addition to the Proton facility investment, the company is actively evaluating inorganic growth opportunities with a focus on existing clusters. The company anticipates that CapEx will consume approximately 50% of EBITDA for brownfield expansion and technical upgrades.

Bed Addition and Hospital Expansion Plans

Fortis Healthcare plans to operationalize an additional 400 beds in the remaining three quarters of FY27. Of these, 200 beds are expected to come from the FMRI facility, with the balance distributed across other expansion initiatives.

Diagnostic Business Guidance

For the Diagnostic Business, management has provided specific financial targets for the remaining quarters of FY27, driven by continued business momentum and an improved business-to-consumer (B2C) mix.

The improvement in the B2C mix is expected to be a key driver supporting the diagnostic segment's margin profile through the remainder of the fiscal year.

Summary

Fortis Healthcare's concall guidance reflects a multi-pronged approach to margin expansion, combining new unit ramp-ups, improved collections, and capacity additions. The approval of a INR252 crore Proton facility CapEx at Gurgaon, alongside plans to add 400 beds in FY27, underscores the company's ongoing investment in its hospital network. The Diagnostic Business is expected to deliver 12-13% revenue growth with EBITDA margins in the 24-25% range for the remaining quarters of FY27, while the consolidated business targets a 25% EBITDA margin by FY28.